Criteria Used to Determine Platinum Eligibility in Patients with Metastatic Urothelial Carcinoma: Results of a Physician Survey in Five European Countries
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.European physicians consider most metastatic urothelial carcinoma patients eligible for platinum chemotherapy. Ineligibility criteria align with US data, except for an 80-year age threshold, potentially improving care standardization.
Area Of Science
- Oncology
- Urology
- Clinical Practice
Background
- Platinum-based chemotherapy is a standard first-line treatment for metastatic urothelial carcinoma (mUC).
- Real-world platinum-ineligibility criteria used by European physicians are not well-defined.
- Understanding these criteria is crucial for consistent patient management.
Purpose Of The Study
- To assess factors and clinical thresholds European physicians use to determine platinum ineligibility in mUC patients.
- To compare European criteria with published US thresholds.
Main Methods
- A quantitative online survey was conducted among 503 physicians (oncologists and urologists) in France, Germany, Italy, Spain, and the UK.
- Physicians reported patient eligibility rates and ineligibility factors.
- European consensus thresholds were established and compared to US data.
Main Results
- 77% of treated mUC patients were deemed platinum eligible by European physicians.
- European consensus thresholds for ineligibility included creatinine clearance <25 mL/min or peripheral neuropathy grade ≥3.
- A key difference was a European consensus age threshold of 80 years, unlike the US study.
Conclusions
- European physicians generally consider most mUC patients eligible for platinum chemotherapy.
- Ineligibility criteria show broad consistency with US findings, with age being a notable exception.
- Standardizing these criteria could enhance decision-making, reduce care variability, and improve patient outcomes.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.